Medtronic to create European software hub in Ireland
Medtronic is establishing a European software hub in Galway, Ireland, focused on developing cloud-based platforms and clinical software for cardiac patients with implanted devices. This investment will initially create 85 jobs, with further growth anticipated over the next three years. The move expands Medtronic's presence in Ireland, where it already has its corporate headquarters, and reflects a broader strategy including a global AI and robotics hub in London, and consolidation of cardiology businesses.
Elyra Kidney Stone Laser Launch Tests Becton Dickinson Execution Story
Becton Dickinson (NYSE:BDX) has launched the Elyra Thulium Fiber Laser System for kidney stone procedures, expanding its urologic stone management portfolio in the United States. This launch tests the company's execution capabilities amidst a mixed stock performance, a microbiology pouch recall, and new leadership in BD Interventional. Investors will be watching the adoption rate of the Elyra system and the company's ability to maintain product reliability and address its debt levels.
Zacks Industry Outlook Highlights Electromed, Globus Medical and Intuitive Surgical
This Zacks Industry Outlook highlights Electromed (ELMD), Globus Medical (GMED), and Intuitive Surgical (ISRG) as key players poised to thrive in the medical instruments industry, driven by the increasing adoption of generative AI. The article details how AI is transforming medical diagnostics, surgeries, and drug development, despite industry challenges such as global economic slowdowns and inflation. It also discusses M&A trends and the current market valuation for medical instrument stocks.
Boston Scientific director Cheryl Pegus buys $99,987 in stock
Boston Scientific director Cheryl Pegus recently purchased 1,770 shares of the company's common stock for approximately $99,987. This insider buying occurred despite a 46% decline in the stock over the past year. The announcement coincides with several positive developments for Boston Scientific, including successful clinical trials, a major equity investment in MiRus, and a significant share repurchase program, all of which have led to optimistic analyst ratings.
Director Edward J. Ludwig buys 3,580 Boston Scientific (BSX) shares in open market
Boston Scientific director Edward J. Ludwig purchased 3,580 shares of common stock at $56.68 per share in an open-market transaction on May 20, 2026. This acquisition increased his direct ownership to 25,359 shares and was reported via a Form 4 filing, indicating a positive sentiment. The total value of the transaction was $202,914.
Boston Scientific (NYSE: BSX) director adds 4,450 company shares
Boston Scientific director David C. Habiger recently purchased 4,450 shares of the company's common stock in two open-market transactions on May 19 and 20, 2026. These purchases, totaling approximately $251,098, increased his direct holdings to 13,878 shares. The average purchase prices were $56.9451 per share on May 19 and $55.9195 per share on May 20.
Boston Scientific director Ludwig buys $202,914 in stock
Edward J. Ludwig, a director at Boston Scientific Corp. (NYSE:BSX), recently purchased 3,580 shares of company stock for $202,914, increasing his direct holdings to 25,359 shares. This transaction follows other significant company developments, including positive trial results for its FRACTURE and SEISMIQ devices, a $1.5 billion equity investment in MiRus, and a $2 billion accelerated share repurchase agreement. Analysts from Truist Securities, TD Cowen, and Piper Sandler have reiterated Buy or Overweight ratings, with price targets ranging from $80.00 to $90.00, reflecting confidence in Boston Scientific's strategic moves and product performance.
FDA warns public about Johnson & Johnson heart pump controllers after patient death
The FDA has issued a warning regarding a software error in Johnson & Johnson MedTech’s Automated Impella Controllers (AICs) when used with left ventricular Impella devices, which has been linked to two serious injuries and one patient death. The issue can cause the device to restart, leading to a 35-second period where the patient is unsupported, potentially resulting in serious harm or death if alternative mechanical support is not in place. Johnson & Johnson MedTech is developing a software update, and while no devices need to be returned, customers have received instructions on how to respond to unexpected reboots.
Neogen Corp stock (US6404911066): share jumps after strong quarterly update and integration progress
Neogen Corp's stock experienced a jump following a strong quarterly report that highlighted solid growth in food safety testing and significant progress in integrating the acquired 3M food safety business. The company's focus on food safety solutions and animal health products, alongside strategic acquisitions and ongoing innovation, are key drivers. Investors are closely watching the company's ability to convert revenue growth into sustained margin expansion as it continues to integrate the 3M assets and optimize its global footprint.
Johnson & Johnson MedTech Chief Just Revealed What’s Coming for the EP Market. Here’s What Investors Should Know
Johnson & Johnson's MedTech Electrophysiology and Neurovascular Group Chair, Michael Bodner, unveiled a comprehensive product roadmap for the EP market at the RBC Capital Markets Global Healthcare Conference. This includes a complete EP ecosystem, new product name disclosures like ISOPULSE, and clinical data supporting J&J's competitive position in the growing $16 billion electrophysiology market. The article suggests J&J's valuation, especially given new product launches and market expansion, may be underestimated by current Street consensus, emphasizing key signals like Q3 2026 EP revenue and PERSIGMA trial results for investors to watch.
Medtronic to acquire SPR Therapeutics for $650m
Medtronic is set to acquire SPR Therapeutics for approximately $650 million, enhancing its offerings in peripheral nerve stimulation (PNS) for chronic pain management. This acquisition will integrate SPR's SPRINT PNS System, an FDA-cleared temporary therapy, into Medtronic's neuromodulation solutions. The deal aims to provide earlier intervention options for chronic pain patients and is expected to close in the first half of Medtronic's fiscal year 2027.
Buying pulsed field ablation systems: What hospitals should know
The article discusses factors hospitals should consider when purchasing pulsed field ablation systems due to the crowded market. It lists several companies offering these systems, including Boston Scientific, Abbott, Medtronic, Johnson & Johnson MedTech, and Kardium Inc. The piece is part of a series covering medical devices.
Boston Scientific’s strategic investment in MiRus includes option to acquire TAVR system
Boston Scientific has invested $1.5 billion in MiRus LLC for an approximately 34% equity stake, securing an exclusive option to acquire the MiRus TAVR system. This investment focuses on the SIEGEL Balloon Expandable Transcatheter Aortic Valve Replacement (TAVR) system, a nickel-free, balloon-expandable TAVR valve designed to treat severe aortic stenosis. The potential acquisition, valued at an additional $3 billion upon successful completion of milestones, aims to accelerate the commercial launch of this innovative technology and enhance Boston Scientific's cardiology portfolio.
Axonics Inc stock (US05465P1012): Boston Scientific takeover puts sacral neuromodulation specialist
Axonics Inc, a specialist in sacral neuromodulation for incontinence, is being acquired by Boston Scientific in a multi-billion dollar cash deal for $71 per share. This acquisition highlights the growing interest in minimally invasive urology solutions and the strategic value of Axonics' therapies. The deal, which will lead to Axonics' delisting from Nasdaq, merges its innovative technology into a larger diversified medical device portfolio, raising questions about future integration and market impact.
Analysts Conflicted on These Healthcare Names: Design Therapeutics (DSGN), Pro Medicus Limited (OtherPMCUF) and Boston Scientific (BSX)
Analysts are sharing conflicting opinions on several healthcare companies, including Design Therapeutics (DSGN), Pro Medicus Limited (PMCUF), and Boston Scientific (BSX). RBC Capital analysts maintained Buy ratings on Design Therapeutics and Boston Scientific, with price targets of $20.00 and $100.00 respectively, while maintaining a Hold rating on Pro Medicus Limited with a target of A$195.00. The consensus for all three stocks remains a Strong Buy with significant potential upside.
Medtronic to buy SPR Therapeutics for about $650M
Medtronic announced its agreement to acquire SPR Therapeutics for $650 million in cash, marking its third major acquisition this year. This deal will expand Medtronic's neuromodulation business by adding SPR Therapeutic's Sprint peripheral nerve stimulation device, which treats chronic pain without requiring a permanent implant. The acquisition is expected to close within the first half of Medtronic's 2027 fiscal year, pending regulatory approvals.
CONMED Adds Former Johnson & Johnson and Boston Scientific Executives to Board
CONMED Corporation has announced the appointment of Celine Martin and Jeff Mirviss, former executives from Johnson & Johnson and Boston Scientific respectively, to its board of directors. These additions aim to bolster CONMED's strategic oversight and enhance its competitive edge in the MedTech industry, leveraging their extensive experience in surgical technology, global commercialization, and operational leadership. The appointments highlight the evolving governance priorities in MedTech, which increasingly favor operational and commercialization expertise alongside financial oversight.
Medtronic to spend $650M on 60-day nerve therapy for chronic pain
Medtronic (NYSE: MDT) plans to acquire SPR Therapeutics, a leader in temporary peripheral nerve stimulation (PNS) for chronic pain, for approximately $650 million in cash. This acquisition will add SPR’s 60-day, FDA-cleared SPRINT PNS System to Medtronic’s neuromodulation portfolio, aiming to expand care options for chronic pain sufferers. The deal is expected to close in the first half of Fiscal 2027, subject to regulatory approvals.
Medtronic announces intent to acquire SPR Therapeutics, Inc., expanding care options for people living with chronic pain
Medtronic plc announced its intent to acquire SPR Therapeutics, Inc. for approximately $650 million. This acquisition will enhance Medtronic's Neuromodulation portfolio by adding temporary peripheral nerve stimulation (PNS) technology, specifically the SPRINT® PNS System, to provide earlier intervention options for chronic pain sufferers. The transaction is expected to close in the first half of Medtronic's Fiscal Year 2027.
Conmed appoints two directors to board effective July 1
CONMED Corporation announced the appointment of Celine Martin and Jeff Mirviss to its board of directors, effective July 1, 2026, expanding the board from seven to nine members. Martin, formerly of Johnson & Johnson, will join the audit and strategy committees. Mirviss, with extensive healthcare experience from Boston Scientific, will serve on the compensation and corporate governance committees.
Abbott's Biosimilar Push to Help Sustain EPD Growth Momentum
Abbott's Established Pharmaceuticals Division (EPD) has consistently driven growth, with biosimilars identified as a key pillar for future expansion. The company's strategy involves leveraging partnerships and its broad presence in emerging markets to commercialize biosimilars in oncology, women's health, and respiratory diseases. Despite recent stock performance challenges, Abbott aims to sustain EPD's growth momentum through these initiatives.
New CONMED (NYSE: CNMD) directors, bylaw changes and 2026 vote outcomes
CONMED Corporation (NYSE: CNMD) made several governance updates, including expanding its board to nine directors and appointing Celine Martin and Jeff Mirviss as independent directors, effective July 1, 2026. The company also amended its bylaws to update advance notice provisions for stockholder nominations and approved the advisory vote on executive compensation and the ratification of PricewaterhouseCoopers LLP as its independent registered public accounting firm for fiscal 2026 at its annual meeting. Additionally, Kimberly Lockwood was appointed interim Corporate Controller and interim Principal Accounting Officer.
Baird Maintains Bullish View on Boston Scientific (BSX) Despite Lower Target
Baird has reiterated an Outperform rating on Boston Scientific (BSX) but lowered its price target to $75 from $78, following the company's re-entry into the TAVR market. This move is expected to provide modest accretion. Concurrently, BofA also reduced its price goal to $68 from $105, citing a "new reality of medtech valuations," while Boston Scientific announced a $2 billion accelerated share repurchase agreement.
Boston Scientific Corp. stock (US10117L1017): market eyes next catalysts after recent updates
Boston Scientific Corp. remains a significant player in the medical technology sector, focusing on minimally invasive cardiovascular and interventional procedures. The company's recent product and regulatory updates have kept it in investor focus, with expectations for future growth tied to its pipeline and ongoing innovations. Investors are closely watching key revenue drivers in cardiovascular, electrophysiology, urology, and endoscopy markets, along with the company's strategic acquisitions and clinical evidence development.
Boston jury orders Takeda to pay $885M over delayed generic drug launch
A federal jury in Boston has ordered Takeda to pay $885 million in damages in an antitrust case. The pharmaceutical company was found liable for delaying the launch of a generic version of a drug used to treat chronic constipation. Takeda has its U.S. operations based in Cambridge, Massachusetts.
Boston Scientific Advances Coronary Calcium Treatment With Positive Trial Results
Boston Scientific announced positive pivotal trial data for its investigational SEISMIQ 4CE Coronary Intravascular Lithotripsy catheter. The device met both primary safety and effectiveness goals for treating severely calcified coronary artery disease in a study of 420 patients. This technology uses laser-generated acoustic pressure waves to fracture calcium buildup, aiming to improve stent placement outcomes.
Boston Scientific stock rating reiterated at Buy by TD Cowen
TD Cowen has reiterated a Buy rating and an $80.00 price target for Boston Scientific (NYSE:BSX), citing expectations for the success of their Seismiq device's FRACTURE IDE study. The firm anticipates this will enable Boston Scientific to enter the U.S. coronary intravascular lithotripsy market by the first half of 2027, projecting it to become a $1.5 billion market with double-digit growth. This positive outlook is supported by recent clinical trial successes, a significant share repurchase agreement, and strategic equity investments.
Abbott Spinal Cord Stimulator Problems Resulted in Severe Paralysis: Lawsuit
A new lawsuit alleges that Abbott's Proclaim Plus 5 spinal cord stimulator malfunctioned, causing the patient to suffer repeated electric shocks, leading to progressive loss of mobility and eventual paralysis from the waist down. The plaintiff, Ray Lavigne, claims the device was ineffective from the start and that Abbott continued to reprogram it despite warnings, ultimately requiring surgical removal. The lawsuit also names the U.S. Food and Drug Administration, arguing the implant should not have been approved for the market.
Press Release: Merit Medical Shareholders Elect Scott R. Ward to Board of Directors
Merit Medical Systems, Inc. announced that its shareholders elected Scott R. Ward to the company's Board of Directors during its 2024 annual meeting. The appointment of Mr. Ward, who brings extensive experience from his leadership roles at Boston Scientific Corporation, expands the Board to twelve members. His expertise is expected to contribute to Merit Medical's ongoing growth and strategic objectives.
Trial of new heart device leaves 93% free of major cardiac events
Boston Scientific's FRACTURE IDE trial for its SEISMIQ 4CE Coronary IVL Catheter met its primary safety and effectiveness endpoints, showing 93.3% freedom from major adverse cardiac events at 30 days and 93.7% procedural success in patients with severe coronary artery disease. This positive data supports regulatory submission for the device, which uses laser energy to treat calcified arteries and improve stent placement. The trial, involving 420 patients across 46 sites, will continue with a two-year follow-up.
Henry Schein stock (US42548G1040): dental distributor in focus after latest quarterly update
Henry Schein, a major dental and medical distributor, recently released new quarterly figures and an updated outlook, drawing investor attention. The article examines the company's business model, key revenue drivers in its dental and medical segments, and the impact of factors like inflation and procedure volumes on its performance. It concludes that while Henry Schein maintains a strong position through recurring sales and technology offerings, it faces ongoing challenges from economic cycles and competitive pricing.
Has The Recent Slide In Abbott Laboratories (ABT) Opened Up A Valuation Opportunity?
Abbott Laboratories (ABT) stock has seen a significant decline over the past year, but a recent analysis by Simply Wall St suggests it may now be undervalued. Using a Discounted Cash Flow (DCF) model and Price-to-Earnings (P/E) ratio comparison, the article indicates that ABT could be trading at a substantial discount to its intrinsic value. Investors are encouraged to explore different valuation narratives to form their own conclusions about the stock's potential.
Autonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validation
Autonomix Medical, Inc. (NASDAQ: AMIX) has announced that the U.S. Patent and Trademark Office granted it U.S. Patent No. 12,544,131, titled “Systems, Methods, and Devices for Monitoring and Treatment of Tissues Within And/Or Through a Lumen Wall.” This patent strengthens the company's intellectual property for next-generation neuromodulation technologies, enabling real-time transvascular monitoring and treatment. The technology aims to enhance procedural outcomes by allowing objective, real-time confirmation of nerve treatment effectiveness and dynamic therapy adjustment, particularly for conditions like pancreatic cancer pain.
Here's How Much You Would Have Made Owning Boston Scientific Stock In The Last 15 Years
Boston Scientific (NYSE: BSX) has delivered an average annual return of 15.23% over the past 15 years, outperforming the market by 3.06% on an annualized basis. An initial investment of $1000 in BSX stock 15 years ago would now be worth $8,511.42. This highlights the significant impact of compounded returns on investment growth over time.
Boston Scientific Corp (BSX) Stock Up 6.2% and Still Undervalued -- GF Score: 83/100
Boston Scientific Corp (BSX) shares rose 6.2% to $55.92, despite a challenging year. The stock is considered significantly undervalued by GuruFocus's GF Value™ at $104.85, indicating a potential 46.7% upside. With a strong GF Score™ of 83/100 and high ratings in Growth and Profitability, BSX presents a possible opportunity, though recent momentum and historical valuation trends suggest caution.
J&J Has 'No Intention' of Giving Up IVL Market Leadership
Johnson & Johnson's subsidiary, Shockwave Medical, is asserting its continued dominance in the Intravascular Lithotripsy (IVL) market with the global launch of its fifth-generation C2 Aero system. Despite increasing competition from other major medical device companies, Shockwave's Chief Medical Officer, Nick West, emphasizes their commitment to market leadership, citing extensive clinical evidence, a robust reimbursement framework, and continuous R&D with plans for annual product launches. The company differentiates itself by defining true IVL as energy-based and focusing on enhanced deliverability and patient outcomes, even exploring new applications in carotid and structural heart diseases.
Envoy Medical shareholders approve plan amendments and board elections at annual meeting
Envoy Medical shareholders approved amendments to the company's 2023 Equity Incentive Plan and 2023 Employee Stock Purchase Plan, authorizing additional shares. They also elected Brent T. Lucas and Susan J. Kantor to the board, ratified EisnerAmper, LLP as the independent accounting firm, and approved executive compensation. These decisions were made during the 2026 Annual Meeting of Stockholders on May 12, alongside the approval of warrants for Class A Common Stock issued earlier in the year.
Luminex Multiplex Assays Market Projected to Reach USD 3.89 Billion by 2033, Driven by Rising Demand for High-Throughput Biomarker Profiling and Standardized Multiplex Testing Workflows: Verified Market Research
The global Luminex Multiplex Assays Market is projected to reach USD 3.89 billion by 2033, growing at a CAGR of 10.0% from its 2025 valuation of USD 1.82 billion. This growth is driven by the increasing adoption of multiplex assay technologies for high-throughput biomarker profiling, the rising demand for panel scalability, and the shift towards standardized, throughput-oriented laboratory workflows across various sectors including clinical diagnostics, pharmaceutical research, and academic research. The market overview details its focus on bead-based multiplex immunoassay technologies and outlines key drivers, opportunities, challenges, and competitive landscape, with North America leading regional contributions.
Boston Scientific Corp Stock (BSX) Closed Up by 5.88% on May 18: Facts Behind the Movement
Boston Scientific Corp (BSX) stock closed up by 5.88% on May 18, driven by a strategic $1.5 billion investment in MiRus LLC, including an option to acquire its TAVR business. Further boosting investor confidence, the company initiated a $2 billion accelerated share repurchase agreement following strong Q1 2026 financial results that surpassed expectations. These actions, coupled with reaffirmed "Buy" or "Outperform" ratings from analysts, contributed to the significant upward movement despite some technical indicators suggesting caution.
Boston Scientific Targets Growing Aortic Stenosis Market With $1.5 Billion Deal
Boston Scientific has invested $1.5 billion in MiRus, acquiring an approximately 34% equity stake and an exclusive option to fully acquire MiRus's investigational transcatheter aortic valve replacement (TAVR) business for an additional $3 billion upon meeting clinical and regulatory milestones. This strategic move aims to strengthen Boston Scientific's cardiovascular portfolio by gaining access to the SIEGEL Balloon Expandable TAVR system, a nickel-free valve platform designed for severe aortic stenosis. The SIEGEL valve boasts enhanced radial strength, precise placement, and a smaller delivery profile, currently undergoing the STAR pivotal trial.
Boston Scientific Bets on Growth Through Strategic M&A Deals
Boston Scientific is focusing on strategic mergers and acquisitions to drive growth, expand into new areas, and strengthen its market position, exemplified by recent acquisitions in urology and pain management. The company also announced a definitive agreement to acquire Penumbra to enter fast-growing vascular segments. Meanwhile, peers like Abbott Laboratories and Medtronic are also pursuing significant M&A activities to expand their portfolios and market reach.
Boston Scientific returns to heart-valve market with $1.5B investment in startup
Boston Scientific is re-entering the heart-valve market with a significant $1.5 billion investment in startup MiRus, just a year after exiting the sector. This strategic move includes a pathway for a potential larger acquisition of MiRus in the future. The investment signals Boston Scientific's strong commitment to re-establishing its presence in the heart valve replacement space.
BD taps former J&J leader as new president of Interventional
BD has appointed Peter Menziuso, a former Johnson & Johnson Vision leader, as the new EVP and president of its Interventional segment, effective June 1. Menziuso will succeed Rick Byrd, who announced his retirement last month. With over 30 years in the healthcare industry, Menziuso is expected to drive continued growth for BD Interventional, which focuses on surgical, endovascular, urological, and critical care solutions.
Boston Scientific stock gains on $2B share buyback plan
Boston Scientific Corp (BSX) shares rose 2.1% in premarket trading after the company announced a $2 billion accelerated share repurchase agreement. The company also disclosed a $1.5 billion investment for approximately a 34% equity stake in MiRus LLC, a privately-held company focused on cardiovascular and orthopedic treatments. This investment includes an exclusive option to acquire the MiRus TAVR system, a novel nickel-free, balloon-expandable transcatheter aortic valve replacement system.
Boston Scientific stock gains on $2B share buyback plan
Boston Scientific's shares rose after the company announced a $2 billion accelerated share repurchase agreement, part of a larger $5 billion authorization. Concurrently, Boston Scientific made a $1.5 billion investment for a 34% equity stake in MiRus LLC, a company developing cardiovascular and orthopedic treatments, including a novel TAVR system, with an exclusive option to acquire the TAVR business. The share repurchase is expected to boost adjusted EPS by $0.02 in 2026, while the MiRus investment is anticipated to have an immaterial impact on 2026 adjusted EPS.
Wearables in Pharma & Biotech Research and Forecasts Report 2026-2031, Company Profiles and Market Strategies of Abbott, Dexcom, and Masimo
The wearables in the pharma & biotech market are projected to grow significantly from USD 3.98 billion in 2026 to USD 9.97 billion by 2031, driven by advancements in biosensor technology, miniaturization, and digitization, alongside increasing global internet connectivity. Continuous Glucose Monitors (CGMs) currently lead the product segment due to strong clinical backing and expanding patient eligibility. Pharmaceutical and biotech companies are the largest end-users, with Asia Pacific showing the highest growth potential due to its improving digital health infrastructure and increasing clinical research.
Fermi Files With SEC To Block Ousted CEO From Hosting Special Shareholder Meet – ‘His Behavior As CEO Created Disruption To Operations’
Energy grid developer Fermi Inc. (FRMI) has filed with the SEC to prevent its ousted CEO, Toby Neugebauer, from calling a special shareholder meeting, aiming to block his efforts to regain control. Fermi claims Neugebauer was fired for misrepresentations, breach of fiduciary duties, and conduct that disrupted operations and damaged key business relationships. The company's board fears Neugebauer will force a sale that benefits him and harms public shareholders, and has proposed bylaw changes to prevent this, despite Neugebauer's accusations of entrenchment.
Boston Scientific invests $1.5 billion in MiRus with option to buy heart-valve business
Boston Scientific has invested $1.5 billion in privately-held MiRus LLC, acquiring a 34% equity stake and gaining potential access to MiRus's heart-valve business. This deal marks Boston Scientific's re-entry into the balloon-expandable transcatheter aortic valve replacement (TAVR) market. The agreement includes an option for Boston Scientific to acquire MiRus's TAVR business for an additional $3 billion if certain clinical and regulatory milestones are met, with MiRus also eligible for future sales-based payments.
Boston Scientific (NYSE: BSX) starts $2B accelerated share repurchase program
Boston Scientific (NYSE: BSX) has initiated a $2 billion accelerated share repurchase (ASR) program with JPMorgan Chase Bank, as part of its existing $5 billion authorization. The company will initially receive approximately 30.4 million shares, with the final number to be determined by the volume-weighted average price during the ASR term. This move is expected to increase adjusted earnings per share for full-year 2026 by $0.02 and leaves $3 billion remaining under the initial authorization.
Boston Scientific is spending $2 billion buying back its own stock
Boston Scientific (NYSE: BSX) has initiated a $2 billion accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank, as part of its existing $5 billion authorization. The company will initially receive about 30.4 million shares and expects the ASR to boost its full-year 2026 adjusted EPS by $0.02. The final settlement of the ASR is anticipated by June 30, 2026, after which $3 billion will remain under the repurchase authorization.
